Kentaro Tsuji-Naito
Research Subjects
Kentaro Tsuji-Naito has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Natsuko Kitajima
DHC Corporation Laboratories, Division 2
5 shared publications- Takahisa Nakajo
DHC Corporation Laboratories, Division 2, 2-42 Hamada, Mihama-ku, Chiba, 261-0025, Japan
5 shared publications - Takeshi Katayoshi
DHC Corporation Laboratories, Division 2, 2-42 Hamada, Mihama-ku, Chiba, 261-0025, Japan
5 shared publications - Natsuko Kitajima
DHC Corporation Laboratories, Division 2, 2-42 Hamada, Mihama-ku, Chiba, 261-0025, Japan
4 shared publications Takeshi Katayoshi
DHC Corporation Laboratories, Division 2
4 shared publicationsKumiko Kobayashi-Nakamura
DHC Corporation, Fundamental Research Laboratory, Division 2, 2-42 Hamada, Mihama-ku, Chiba, 261-0025, Japan
3 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (10) , e71187
Intracellular NAD + Depletion Increases Prostanoid Production via p38/ COX2 Signalling in FK866 ‐Induced Senescent Human Umbilical Vein Endothelial Cells
Vascular endothelial cells maintain vascular homeostasis by releasing mediators with vasoconstrictive and vasorelaxant effects. Prostanoids are bioactive substances synthesised by cyclooxygenase2 (COX2); they preserve vascular function and can increase the risk of cardiovascular disease (CVD) associated with ageing. Age‐related reductions in nicotinamide adenine dinucleotide (NAD + ) have been implicated in CVD pathogenesis. However, the relationship between intracellular NAD + levels and prostanoid production in vascular endothelial cells is unclear. Herein, reduced intracellular NAD + levels upregulated COX2 protein expression by activating the p38 mitogen‐activated protein kinase (MAPK) signalling pathway, increasing the production of prostaglandin F 1α (PGF 1α ) and thromboxane B 2 (TXB 2 ) in human umbilical vein endothelial cells (HUVECs). Treatment with the nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, FK866, decreased intracellular NAD + levels, induced a cellular senescence‐like phenotype characterised by the suppression of cell proliferation without cell death and promoted PGF 1α and TXB 2 production in HUVECs. FK866 treatment increased phosphorylated p38 and COX2 protein levels, whereas treatment with the p38 inhibitor, PD169316, suppressed the FK866‐induced increase in COX2 expression. Supplementation with nicotinamide mononucleotide (NMN), a precursor of NAD + , following FK866 treatment restored intracellular NAD + levels, reduced the cellular senescence‐like phenotype and attenuated the production of PGF 1α and TXB 2 . These results suggest that intracellular NAD + appears to regulate prostanoid production in HUVECs under conditions of acute depletion.
- 20 May 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (10) , e71187
Open AccessIntracellular NAD + Depletion Increases Prostanoid Production via p38/ COX2 Signalling in FK866 ‐Induced Senescent Human Umbilical Vein Endothelial Cells
Vascular endothelial cells maintain vascular homeostasis by releasing mediators with vasoconstrictive and vasorelaxant effects. Prostanoids are bioactive substances synthesised by cyclooxygenase2 (COX2); they preserve vascular function and can increase the risk of cardiovascular disease (CVD) associated with ageing. Age‐related reductions in nicotinamide adenine dinucleotide (NAD + ) have been implicated in CVD pathogenesis. However, the relationship between intracellular NAD + levels and prostanoid production in vascular endothelial cells is unclear. Herein, reduced intracellular NAD + levels upregulated COX2 protein expression by activating the p38 mitogen‐activated protein kinase (MAPK) signalling pathway, increasing the production of prostaglandin F 1α (PGF 1α ) and thromboxane B 2 (TXB 2 ) in human umbilical vein endothelial cells (HUVECs). Treatment with the nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, FK866, decreased intracellular NAD + levels, induced a cellular senescence‐like phenotype characterised by the suppression of cell proliferation without cell death and promoted PGF 1α and TXB 2 production in HUVECs. FK866 treatment increased phosphorylated p38 and COX2 protein levels, whereas treatment with the p38 inhibitor, PD169316, suppressed the FK866‐induced increase in COX2 expression. Supplementation with nicotinamide mononucleotide (NMN), a precursor of NAD + , following FK866 treatment restored intracellular NAD + levels, reduced the cellular senescence‐like phenotype and attenuated the production of PGF 1α and TXB 2 . These results suggest that intracellular NAD + appears to regulate prostanoid production in HUVECs under conditions of acute depletion.
- Open Access
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1748872
NMN protects vascular endothelial cells from M1 macrophage-derived IL-1β-induced hyperpermeability by inhibiting VE-cadherin degradation
Background and aims: Vascular endothelial (VE) dysfunction, particularly endothelial hyperpermeability, is a critical pathological process in various inflammatory vascular diseases, including atherosclerosis, vasculitis, and sepsis. Nicotinamide mononucleotide (NMN), an NAD + precursor, has shown anti-inflammatory and vascular protective effects in preclinical models. However, the mechanisms by which NMN preserves endothelial barrier integrity against macrophage-derived inflammatory stimuli remain unclear. This study examined the potential protective role of NMN in endothelial hyperpermeability induced by pro-inflammatory macrophages. Methods: A three-dimensional co-culture model of human umbilical vein endothelial cells (HUVECs) and M1 macrophages was constructed to reproduce inflammatory vascular microenvironments. Endothelial permeability was evaluated by measuring fluorescently labelled dextran and LDL passages from the luminal (top) to the abluminal side (bottom) of the insert. Results: M1 macrophage co-culture increased HUVEC permeability, and NMN pretreatment attenuated this hyperpermeability. Mechanistic analysis revealed that interleukin-1β (IL-1β) released by M1 macrophages was the primary contributor to endothelial hyperpermeability. NMN suppressed IL-1β-induced cell-cell gap formation and VE-cadherin degradation in HUVECs by inhibiting nuclear factor kappa B (NF- κ B) pathway activation. These findings indicate that NMN prevents IL-1β-induced NF- κ B activation and subsequent VE-cadherin degradation, thereby protecting against endothelial hyperpermeability caused by intercellular gap formation. Other NAD + precursors, including nicotinamide riboside, similarly protected against IL-1β-induced hyperpermeability and VE-cadherin degradation. Alternatively, the NAD + -dependent deacetylase sirtuin 1 (SIRT1) inhibitor EX527 or SIRT1 siRNA knockdown abrogated NMN-mediated suppression of hyperpermeability and VE-cadherin degradation. Therefore, the protective effect of NMN against IL-1β-mediated endothelial dysfunction is dependent on the NAD + - SIRT1 axis. Conclusions: This in vitro mechanistic study suggests that the NAD⁺ - SIRT1 axis contributes to IL-1β-induced endothelial barrier disruption, supporting further investigation of NMN in inflammatory vascular diseases.
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1748872
Open AccessNMN protects vascular endothelial cells from M1 macrophage-derived IL-1β-induced hyperpermeability by inhibiting VE-cadherin degradation
Background and aims: Vascular endothelial (VE) dysfunction, particularly endothelial hyperpermeability, is a critical pathological process in various inflammatory vascular diseases, including atherosclerosis, vasculitis, and sepsis. Nicotinamide mononucleotide (NMN), an NAD + precursor, has shown anti-inflammatory and vascular protective effects in preclinical models. However, the mechanisms by which NMN preserves endothelial barrier integrity against macrophage-derived inflammatory stimuli remain unclear. This study examined the potential protective role of NMN in endothelial hyperpermeability induced by pro-inflammatory macrophages. Methods: A three-dimensional co-culture model of human umbilical vein endothelial cells (HUVECs) and M1 macrophages was constructed to reproduce inflammatory vascular microenvironments. Endothelial permeability was evaluated by measuring fluorescently labelled dextran and LDL passages from the luminal (top) to the abluminal side (bottom) of the insert. Results: M1 macrophage co-culture increased HUVEC permeability, and NMN pretreatment attenuated this hyperpermeability. Mechanistic analysis revealed that interleukin-1β (IL-1β) released by M1 macrophages was the primary contributor to endothelial hyperpermeability. NMN suppressed IL-1β-induced cell-cell gap formation and VE-cadherin degradation in HUVECs by inhibiting nuclear factor kappa B (NF- κ B) pathway activation. These findings indicate that NMN prevents IL-1β-induced NF- κ B activation and subsequent VE-cadherin degradation, thereby protecting against endothelial hyperpermeability caused by intercellular gap formation. Other NAD + precursors, including nicotinamide riboside, similarly protected against IL-1β-induced hyperpermeability and VE-cadherin degradation. Alternatively, the NAD + -dependent deacetylase sirtuin 1 (SIRT1) inhibitor EX527 or SIRT1 siRNA knockdown abrogated NMN-mediated suppression of hyperpermeability and VE-cadherin degradation. Therefore, the protective effect of NMN against IL-1β-mediated endothelial dysfunction is dependent on the NAD + - SIRT1 axis. Conclusions: This in vitro mechanistic study suggests that the NAD⁺ - SIRT1 axis contributes to IL-1β-induced endothelial barrier disruption, supporting further investigation of NMN in inflammatory vascular diseases.
- Open Access
- 1 January 2025
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 72 (1.2) , 66-75
Bergenin promotes mitochondrial biogenesis via the AMPK/SIRT1 axis in hepatocytes
Aging and obesity trigger liver mitochondrial decline, impairing liver function and energy metabolism. Effective hepatic mitochondrial biogenesis helps maintain and restore hepatocyte function. The effects of bergenin, a polyphenol with various pharmacological effects, on hepatic mitochondrial biogenesis remain unclear. Therefore, we aimed to determine its effects on mitochondrial biogenesis in hepatocytes. We measured mitochondrial content in human HepG2 hepatocytes using MitoTracker Green FM ; intracellular ATP content using an ATP assay kit ; and mitochondrial DNA (mtDNA) using the ratio of mtDNA to nuclear DNA by qPCR. Protein levels were analyzed using immunoblotting. Nuclear translocation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) was assessed by immunofluorescence staining and immunoblotting. In human HepG2 hepatocytes, bergenin increased mitochondrial content, elevated mitochondrial DNA and constituent proteins, and enhanced intracellular ATP levels and PGC-1α nuclear translocation, possibly promoting mitochondrial biosynthesis. SIRT1 expression was induced in bergenin-treated cells and may be responsible for bergenin-inducible mitochondrial biogenesis, which was abolished by the SIRT1 inhibitor EX-527. Furthermore, bergenin activated AMP-activated protein kinase (AMPK). Compound C, an AMPK inhibitor, abolished bergenin-induced SIRT1 expression and mitochondrial biogenesis. Overall, bergenin activates hepatic mitochondrial biogenesis through the AMPK / SIRT1 axis, which could help to prevent and ameliorate serious aging- and obesity-related liver diseases. J. Med. Invest. 72 : 66-75, February, 2025
- 1 January 2025
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 72 (1.2) , 66-75
Open AccessBergenin promotes mitochondrial biogenesis via the AMPK/SIRT1 axis in hepatocytes
Aging and obesity trigger liver mitochondrial decline, impairing liver function and energy metabolism. Effective hepatic mitochondrial biogenesis helps maintain and restore hepatocyte function. The effects of bergenin, a polyphenol with various pharmacological effects, on hepatic mitochondrial biogenesis remain unclear. Therefore, we aimed to determine its effects on mitochondrial biogenesis in hepatocytes. We measured mitochondrial content in human HepG2 hepatocytes using MitoTracker Green FM ; intracellular ATP content using an ATP assay kit ; and mitochondrial DNA (mtDNA) using the ratio of mtDNA to nuclear DNA by qPCR. Protein levels were analyzed using immunoblotting. Nuclear translocation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) was assessed by immunofluorescence staining and immunoblotting. In human HepG2 hepatocytes, bergenin increased mitochondrial content, elevated mitochondrial DNA and constituent proteins, and enhanced intracellular ATP levels and PGC-1α nuclear translocation, possibly promoting mitochondrial biosynthesis. SIRT1 expression was induced in bergenin-treated cells and may be responsible for bergenin-inducible mitochondrial biogenesis, which was abolished by the SIRT1 inhibitor EX-527. Furthermore, bergenin activated AMP-activated protein kinase (AMPK). Compound C, an AMPK inhibitor, abolished bergenin-induced SIRT1 expression and mitochondrial biogenesis. Overall, bergenin activates hepatic mitochondrial biogenesis through the AMPK / SIRT1 axis, which could help to prevent and ameliorate serious aging- and obesity-related liver diseases. J. Med. Invest. 72 : 66-75, February, 2025
- Open Access
- 6 July 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 731, 150371
NAD+ overconsumption by poly (ADP-ribose) polymerase (PARP) under oxidative stress induces cytoskeletal disruption in vascular endothelial cell
- 6 July 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 731, 150371
Open AccessNAD+ overconsumption by poly (ADP-ribose) polymerase (PARP) under oxidative stress induces cytoskeletal disruption in vascular endothelial cell
- Open Access
- 27 October 2023
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 36, 101561
Nucleotide-binding oligomerization domain protein-1 is expressed and involved in the inflammatory response in human sebocytes
- 27 October 2023
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 36, 101561
Open AccessNucleotide-binding oligomerization domain protein-1 is expressed and involved in the inflammatory response in human sebocytes
- 26 August 2023
- Published by Elsevier in Toxicology in Vitro
- Vol. 93, 105683
Nicotinamide mononucleotide inhibits oxidative stress-induced damage in a SIRT1/NQO-1-dependent manner
- 26 August 2023
- Published by Elsevier in Toxicology in Vitro
- Vol. 93, 105683
Nicotinamide mononucleotide inhibits oxidative stress-induced damage in a SIRT1/NQO-1-dependent manner
- Open Access
- 16 February 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-9
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial
Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD+) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD+ levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD+ metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD+ metabolism in healthy middle-aged adults. Additionally, NMN supplementation showed potential in alleviating arterial stiffness.
- 16 February 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-9
Open AccessNicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial
Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD+) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD+ levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD+ metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD+ metabolism in healthy middle-aged adults. Additionally, NMN supplementation showed potential in alleviating arterial stiffness.
- Open Access
- 29 July 2022
- Published by Springer Nature in Research Square
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial
Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD+) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD+ levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD+ metabolites, the levels of nicotinamide in the blood were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD+ metabolism in healthy middle-aged adults. Additionally, NMN supplementation showed potential in alleviating arterial stiffness.
- 29 July 2022
- Published by Springer Nature in Research Square
Open AccessNicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial
Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD+) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD+ levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD+ metabolites, the levels of nicotinamide in the blood were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD+ metabolism in healthy middle-aged adults. Additionally, NMN supplementation showed potential in alleviating arterial stiffness.
- Open Access
- 1 December 2021
- Published by Elsevier in Redox Biology
- Vol. 48, 102203
1,25-Dihydroxyvitamin D3 attenuates IL-1β secretion by suppressing NLRP1 inflammasome activation by upregulating the NRF2-HO-1 pathway in epidermal keratinocytes
- 1 December 2021
- Published by Elsevier in Redox Biology
- Vol. 48, 102203
Open Access1,25-Dihydroxyvitamin D3 attenuates IL-1β secretion by suppressing NLRP1 inflammasome activation by upregulating the NRF2-HO-1 pathway in epidermal keratinocytes
- 1 January 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 522 (1) , 151-156
Alternate expression of PEPT1 and PEPT2 in epidermal differentiation is required for NOD2 immune responses by bacteria-derived muramyl dipeptide
- 1 January 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 522 (1) , 151-156
Alternate expression of PEPT1 and PEPT2 in epidermal differentiation is required for NOD2 immune responses by bacteria-derived muramyl dipeptide